Tesamorelin 20mg Research Peptide Vial

Tesamorelin 20 mg — Growth Hormone-Releasing Hormone (GHRH) Analog for Metabolic & Body Composition Research

Full Description

Tesamorelin is a synthetic 44-amino acid peptide analog of human growth hormone-releasing hormone (GHRH) with an N-terminal trans-3-hexenoyl modification that enhances stability. It is extensively studied in preclinical and clinical research for its ability to stimulate endogenous growth hormone (GH) secretion from the anterior pituitary, leading to downstream effects on IGF-1 levels, lipolysis, and body composition in models of metabolic dysfunction and visceral adiposity.

What It Is

• Class: Synthetic GHRH receptor agonist (growth hormone secretagogue)

• Concept: Selectively binds pituitary GHRH receptors to promote pulsatile GH release while preserving physiological feedback mechanisms, supporting investigations into fat metabolism, lean mass, and endocrine regulation.

• Format: Research-grade synthetic peptide supplied as a lyophilized powder.

Proposed Mechanisms (Preclinical)

GH/IGF-1 Axis Stimulation

• Binds to GHRH receptors on somatotroph cells in the anterior pituitary, activating adenylate cyclase and increasing intracellular cAMP.

• Stimulates synthesis and pulsatile release of endogenous growth hormone.

Metabolic & Lipolytic Effects

• Elevates circulating IGF-1 levels, which promote lipolysis and inhibit lipogenesis in adipose tissue.

• Enhances fat mobilization, particularly from visceral depots, while supporting lean tissue preservation in metabolic models.

Additional Pathways

• Investigated for modulation of hepatic lipid metabolism and improvements in body composition without disrupting normal glucose regulation in select models.

Selected Research Highlights

• Visceral Adipose Tissue (VAT) Reduction: Demonstrated significant reductions in visceral fat and waist circumference in models of abdominal obesity and HIV-associated lipodystrophy.

• Body Composition: Associated with favorable shifts in fat mass versus lean mass, including preservation or modest increases in lean body mass.

• Hepatic Fat: Explored for reductions in liver fat content and improvements in hepatic lipid profiles in relevant metabolic research models.

• Lipid Metabolism: Studied for beneficial effects on triglycerides and overall lipid parameters secondary to GH axis activation.

• Endocrine Regulation: Maintains physiological feedback loops of the GH/IGF-1 axis while elevating IGF-1 within normal ranges in research settings.

Chemical & Handling Information

• Type: Synthetic 44-amino acid GHRH analog

• Modification: N-terminal trans-3-hexenoyl group for enzymatic stability

• Appearance: White to off-white lyophilized powder

Specifications

• Peptide: Tesamorelin

• Amount: 5 mg per vial

• Form: Lyophilized powder

• Purity: ≥99% (HPLC) – Certificate of Analysis available per lot

• Packaging: Sealed vials suitable for standard laboratory handling

Storage & Stability

• Store lyophilized vials in a cool, dry place protected from light.

• Refrigeration or freezing of the lyophilized peptide is recommended for extended stability according to laboratory SOPs.

• After reconstitution: Store at 2–8 °C for short-term use.

• Long-term storage: Aliquot and freeze at –20 °C or below. Avoid repeated freeze-thaw cycles.